Vigil Neuroscience, Alzheimer's Disease
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025;
William Blair has recently initiated Vigil Neuroscience Inc (VIGL) stock to Outperform rating, as announced on December 4, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had ...
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Key takeaways from the Phase 1 clinical trial ...
Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of ...
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback